Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Plos One
|
April 23, 2015
Disentangling multidimensional spatio-temporal data into their common and aberrant responses
Young Hwan Chang, James Korkola, Dhara N Amin, et al.
Cell Reports
|
May 12, 2026
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, et al.
Cell Reports
|
February 2, 2022
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, et al.
Cell Reports
|
September 7, 2022
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, et al.
Molecular Cancer Research : MCR
|
March 17, 2021
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain
Ana Ruiz-Saenz, Farima Zahedi, Elliott Peterson, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
October 31, 2007
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy
Mark M Moasser, Lisa J Wilmes, Ching Hang Wong, et al.
Breast Cancer Research and Treatment
|
February 11, 2016
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
Marcia R Campbell, Hui Zhang, Shabnam Ziaee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers
Ching Hang Wong, Frederick L Baehner, Danislav S Spassov, et al.
Science Translational Medicine
|
April 8, 2010
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
Dhara N Amin, Natalia Sergina, Deepika Ahuja, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 7, 2026
Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer
Roos Vincken, Samuel T Pasco, Veronica Steri, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Plos One
|
April 23, 2015
Disentangling multidimensional spatio-temporal data into their common and aberrant responses
Young Hwan Chang, James Korkola, Dhara N Amin, et al.
Cell Reports
|
May 12, 2026
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, et al.
Cell Reports
|
February 2, 2022
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, et al.
Cell Reports
|
September 7, 2022
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R Campbell, Ana Ruiz-Saenz, Yuntian Zhang, et al.
Molecular Cancer Research : MCR
|
March 17, 2021
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain
Ana Ruiz-Saenz, Farima Zahedi, Elliott Peterson, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
October 31, 2007
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy
Mark M Moasser, Lisa J Wilmes, Ching Hang Wong, et al.
Breast Cancer Research and Treatment
|
February 11, 2016
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
Marcia R Campbell, Hui Zhang, Shabnam Ziaee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers
Ching Hang Wong, Frederick L Baehner, Danislav S Spassov, et al.
Science Translational Medicine
|
April 8, 2010
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
Dhara N Amin, Natalia Sergina, Deepika Ahuja, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 7, 2026
Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer
Roos Vincken, Samuel T Pasco, Veronica Steri, et al.
Page
of 6